A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

Chao Shan, Antonio E. Muruato, Bruno T D Nunes, Huanle Luo, Xuping Xie, Daniele B A Medeiros, Maki Wakamiya, Robert B. Tesh, Alan Barrett, Tian Wang, Scott Weaver, Pedro F C Vasconcelos, Shannan Rossi, Pei-Yong Shi

Research output: Contribution to journalArticle

107 Citations (Scopus)

Abstract

Zika virus (ZIKV) infection of pregnant women can cause a wide range of congenital abnormalities, including microcephaly, in the infant, a condition now collectively known as congenital ZIKV syndrome. A vaccine to prevent or significantly attenuate viremia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to avert congenital ZIKV syndrome, and might also help to suppress epidemic transmission. Here we report on a live-attenuated vaccine candidate that contains a 10-nucleotide deletion in the 3′ untranslated region of the ZIKV genome (10-del ZIKV). The 10-del ZIKV is highly attenuated, immunogenic, and protective in type 1 interferon receptor–deficient A129 mice. Crucially, a single dose of 10-del ZIKV induced sterilizing immunity with a saturated neutralizing antibody titer, which no longer increased after challenge with an epidemic ZIKV, and completely prevented viremia. The immunized mice also developed a robust T cell response. Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 × 104 infectious focus units (IFU) of 10-del ZIKV caused no mortality, whereas infections with 10 IFU of wild-type ZIKV were lethal. Mechanistically, the attenuated virulence of 10-del ZIKV may be due to decreased viral RNA synthesis and increased sensitivity to type-1-interferon inhibition. The attenuated 10-del ZIKV was incapable of infecting mosquitoes after oral feeding of spiked-blood meals, representing an additional safety feature. Collectively, the safety and efficacy results suggest that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.

Original languageEnglish (US)
JournalNature Medicine
DOIs
StateAccepted/In press - Apr 10 2017

Fingerprint

Viruses
Immunity
Vaccines
Interferon Type I
Viremia
Zika Virus
Pregnant Women
Safety
Microcephaly
Attenuated Vaccines
Viral RNA
T-cells
3' Untranslated Regions
Neutralizing Antibodies
Culicidae
Virulence
Meals
Nucleotides
Blood
Genome

ASJC Scopus subject areas

  • Medicine(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Shan, C., Muruato, A. E., Nunes, B. T. D., Luo, H., Xie, X., Medeiros, D. B. A., ... Shi, P-Y. (Accepted/In press). A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. Nature Medicine. https://doi.org/10.1038/nm.4322

A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. / Shan, Chao; Muruato, Antonio E.; Nunes, Bruno T D; Luo, Huanle; Xie, Xuping; Medeiros, Daniele B A; Wakamiya, Maki; Tesh, Robert B.; Barrett, Alan; Wang, Tian; Weaver, Scott; Vasconcelos, Pedro F C; Rossi, Shannan; Shi, Pei-Yong.

In: Nature Medicine, 10.04.2017.

Research output: Contribution to journalArticle

Shan, Chao ; Muruato, Antonio E. ; Nunes, Bruno T D ; Luo, Huanle ; Xie, Xuping ; Medeiros, Daniele B A ; Wakamiya, Maki ; Tesh, Robert B. ; Barrett, Alan ; Wang, Tian ; Weaver, Scott ; Vasconcelos, Pedro F C ; Rossi, Shannan ; Shi, Pei-Yong. / A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models. In: Nature Medicine. 2017.
@article{da647e469ceb447a83f802313b237f99,
title = "A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models",
abstract = "Zika virus (ZIKV) infection of pregnant women can cause a wide range of congenital abnormalities, including microcephaly, in the infant, a condition now collectively known as congenital ZIKV syndrome. A vaccine to prevent or significantly attenuate viremia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to avert congenital ZIKV syndrome, and might also help to suppress epidemic transmission. Here we report on a live-attenuated vaccine candidate that contains a 10-nucleotide deletion in the 3′ untranslated region of the ZIKV genome (10-del ZIKV). The 10-del ZIKV is highly attenuated, immunogenic, and protective in type 1 interferon receptor–deficient A129 mice. Crucially, a single dose of 10-del ZIKV induced sterilizing immunity with a saturated neutralizing antibody titer, which no longer increased after challenge with an epidemic ZIKV, and completely prevented viremia. The immunized mice also developed a robust T cell response. Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 × 104 infectious focus units (IFU) of 10-del ZIKV caused no mortality, whereas infections with 10 IFU of wild-type ZIKV were lethal. Mechanistically, the attenuated virulence of 10-del ZIKV may be due to decreased viral RNA synthesis and increased sensitivity to type-1-interferon inhibition. The attenuated 10-del ZIKV was incapable of infecting mosquitoes after oral feeding of spiked-blood meals, representing an additional safety feature. Collectively, the safety and efficacy results suggest that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.",
author = "Chao Shan and Muruato, {Antonio E.} and Nunes, {Bruno T D} and Huanle Luo and Xuping Xie and Medeiros, {Daniele B A} and Maki Wakamiya and Tesh, {Robert B.} and Alan Barrett and Tian Wang and Scott Weaver and Vasconcelos, {Pedro F C} and Shannan Rossi and Pei-Yong Shi",
year = "2017",
month = "4",
day = "10",
doi = "10.1038/nm.4322",
language = "English (US)",
journal = "Nature Medicine",
issn = "1078-8956",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - A live-attenuated Zika virus vaccine candidate induces sterilizing immunity in mouse models

AU - Shan, Chao

AU - Muruato, Antonio E.

AU - Nunes, Bruno T D

AU - Luo, Huanle

AU - Xie, Xuping

AU - Medeiros, Daniele B A

AU - Wakamiya, Maki

AU - Tesh, Robert B.

AU - Barrett, Alan

AU - Wang, Tian

AU - Weaver, Scott

AU - Vasconcelos, Pedro F C

AU - Rossi, Shannan

AU - Shi, Pei-Yong

PY - 2017/4/10

Y1 - 2017/4/10

N2 - Zika virus (ZIKV) infection of pregnant women can cause a wide range of congenital abnormalities, including microcephaly, in the infant, a condition now collectively known as congenital ZIKV syndrome. A vaccine to prevent or significantly attenuate viremia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to avert congenital ZIKV syndrome, and might also help to suppress epidemic transmission. Here we report on a live-attenuated vaccine candidate that contains a 10-nucleotide deletion in the 3′ untranslated region of the ZIKV genome (10-del ZIKV). The 10-del ZIKV is highly attenuated, immunogenic, and protective in type 1 interferon receptor–deficient A129 mice. Crucially, a single dose of 10-del ZIKV induced sterilizing immunity with a saturated neutralizing antibody titer, which no longer increased after challenge with an epidemic ZIKV, and completely prevented viremia. The immunized mice also developed a robust T cell response. Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 × 104 infectious focus units (IFU) of 10-del ZIKV caused no mortality, whereas infections with 10 IFU of wild-type ZIKV were lethal. Mechanistically, the attenuated virulence of 10-del ZIKV may be due to decreased viral RNA synthesis and increased sensitivity to type-1-interferon inhibition. The attenuated 10-del ZIKV was incapable of infecting mosquitoes after oral feeding of spiked-blood meals, representing an additional safety feature. Collectively, the safety and efficacy results suggest that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.

AB - Zika virus (ZIKV) infection of pregnant women can cause a wide range of congenital abnormalities, including microcephaly, in the infant, a condition now collectively known as congenital ZIKV syndrome. A vaccine to prevent or significantly attenuate viremia in pregnant women who are residents of or travelers to epidemic or endemic regions is needed to avert congenital ZIKV syndrome, and might also help to suppress epidemic transmission. Here we report on a live-attenuated vaccine candidate that contains a 10-nucleotide deletion in the 3′ untranslated region of the ZIKV genome (10-del ZIKV). The 10-del ZIKV is highly attenuated, immunogenic, and protective in type 1 interferon receptor–deficient A129 mice. Crucially, a single dose of 10-del ZIKV induced sterilizing immunity with a saturated neutralizing antibody titer, which no longer increased after challenge with an epidemic ZIKV, and completely prevented viremia. The immunized mice also developed a robust T cell response. Intracranial inoculation of 1-d-old immunocompetent CD-1 mice with 1 × 104 infectious focus units (IFU) of 10-del ZIKV caused no mortality, whereas infections with 10 IFU of wild-type ZIKV were lethal. Mechanistically, the attenuated virulence of 10-del ZIKV may be due to decreased viral RNA synthesis and increased sensitivity to type-1-interferon inhibition. The attenuated 10-del ZIKV was incapable of infecting mosquitoes after oral feeding of spiked-blood meals, representing an additional safety feature. Collectively, the safety and efficacy results suggest that further development of this promising, live-attenuated ZIKV vaccine candidate is warranted.

UR - http://www.scopus.com/inward/record.url?scp=85017269111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85017269111&partnerID=8YFLogxK

U2 - 10.1038/nm.4322

DO - 10.1038/nm.4322

M3 - Article

JO - Nature Medicine

JF - Nature Medicine

SN - 1078-8956

ER -